IL17A and Atherosclerotic lesion: Anti-TIM-3 antibody treatment also resulted in decreased levels of regulatory T cells (Tregs) in the spleen, peripheral blood, and atherosclerotic lesions of Ldlr-/- mice, and increased the total number and activated percentage of peripheral CD4+T cells, producing more interleukin-17 (IL-17) (60) (Table 3).